Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours

Veterinary Journal

Volumn 189, Issue 1, 2011, Pages 43-48

  Santos, Andreia ^a   Lopes, Célia ^a   Marques, Raquel M ^a   Amorim, Irina ^a   Ribeiro, Jorge ^a   Frias, Carlos ^a   Vicente, Corália ^a   Gärtner, Fátima ^a   De Matos, Augusto ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Canine; Mammary; Neoplasia; Prognosis; UPA

Indexed keywords

KI 67 ANTIGEN; UROKINASE;

ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOG; FEMALE; FOLLOW UP; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; DOG DISEASES; DOGS; FEMALE; FOLLOW-UP STUDIES; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

CANIS FAMILIARIS;

EID: 79959219808     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.05.023     Document Type: Article

References (27)

1. Andreasen P.A., Kjoller L., Christense L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal of Cancer 1997, 72:1-22.
2. Bailey T.R., Paulsen D.B., Sehgal I., Hosgood G. Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs. American Journal of Veterinary Research 2006, 67:1628-1634.
3. Bajou K., Lewall K., Martinez C.R., Soria C., Lu H., Noél A., Foidart J.M. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI and by enhancing their expression. International Journal of Cancer 2002, 100:501-506.
4. Castelló R., Landete J.M., España F., Vázquez C., Fuster C., Almenar S.M., Ramón L.A., Radtke K., Estellés A. Expression of plasminogen activator inhibitors types 1 and 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thrombosis Research 2007, 120:753-762.
5. Dublin E., Hanby A., Patel N.K., Liebman R., Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. American Journal of Pathology 2000, 157:1219-1227.
6. Frandsen T.L., Holst-Hansen C., Nielsen B.S., Christensen I.J., Nyengaard J.R., Carmeliet P., Brünner N. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Research 2001, 61:532-537.
7. Guo Y., Higazi A.A.R., Arakelian A., Sachais B.S., Cines D., Goldfarb R.H., Jones T.R., Kwaan H., Mazar A.P., Rabbani S.A. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumour progression and angiogenesis and induces tumour cell death in vivo. FASEB Journal 2000, 14:1400-1410.
8. Han B., Nakamura M., Zhou G., Ishii A., Nakamura A., Bai Y., Mori I., Kakudo K. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. International Journal of Oncology 2006, 28:807-814.
9. Harbeck N., Kates R.E., Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. Journal of Clinical Oncology 2002, 20:1000-1007.
10. Hildenbrand R., Schaaf A. The urokinase-system in tumour tissue stroma of the breast and breast cancer cell invasion. International Journal of Oncology 2009, 34:15-23.
11. Hildenbrand R., Schaaf A., Dorn-Beineke A., Allgayer H., Sütterlin M., Marx A., Stroebel P. Tumour stroma is the predominant uPA, uPAR, PAI-1 expressing tissue in human breast cancer: prognostic impact. Histology and Histopathology 2009, 24:869-877.
12. Hsu S., Raine L., Fanger H. The use of anti avidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. American Journal of Clinical Pathology 1981, 75:816-821.
13. Konecny G., Untch M., Arboleda J., Wilson C., Kahlert S., Boettcher B., Felber M., Beryt M., Lude S., Hepp H., Slamon D., Pegram M. HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clinical Cancer Research 2001, 7:2448-2457.
14. Lana S.E., Rutteman G.R., Withrow S.J. Tumors of the mammary gland. Small Animal Clinical Oncology 2007, 619-636. Saunders Elsevier, St. Louis. S.J. Withrow, E.G. MacEwen (Eds.).
15. Look, M.P., van Putten, W.L.J., Duffy, M.J., Harbeck, N., Christensen, I.J., Thomssen, C., Kates R., Spyratos, F., Fernö, M., Eppenberger-Castori, S., Sweep, C.G., Ulm, K., Peyrat, J.P., Martin, P.M., Magdelenat, H., Brünner, N., Duggan, C., Lisboa, B.W., Bendahl, P.O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M.E., Manders, P., Fiets, W.E., Blankenstein, M.A., Broët, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L.V., Klijn, J.G., O'Higgins, N., Eppenberger, U., Jänicke, F., Schmitt, M., Foekens, J.A., 2002. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Journal of National Cancer Institute 94, 116-128.
16. Manders P., Tjan-Heijnen V.C.G., Grebenchtchikov N., Geurts-Moespot A., van Tienoven D.T.H., Beex L.V.A.M., Sweep F.C.G.J. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. American Cancer Society 2004, 101:3.
17. Matos A.J.F., Faustino A.M.R., Lopes C., Rutteman G.R., Gärtner F. Detection of lymph node micrometastases in canine malignant mammary tumours with the use of cytokeratin immunostaining. Veterinary Record 2006, 158:626-629.
18. Matos A.J.F., Lopes C., Faustino A.M.R., Carvalheira J., Santos M., Rutteman G.R., Gärtner F. MIB-1 indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. Anticancer Research 2006, 26:1821-1826.
19. Misdorp, W., Else, R.W., Helmén, E., Lipscomb, T.P., 1999. Histological classification of the mammary tumours of the dog and the cat. In: Shulman, Fl., (Ed.), World Health Organization International Histological Classification of Tumours of Domestic Animals, Second Series, vol. 7, Armed Forces Institute of Pathology, Washington, DC, pp. 16-29.
20. Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., Johnsen M., Dano K. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Laboratory Investigation 2001, 81:1485-1501.
21. Nielsen B.S., Rank F., Illeman M., Lund L.R., Dano K. Stromal cells associated whit early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. International Journal of Cancer 2007, 120:2086-2095.
22. Rabbani S.A., Gladu J. Urokinase receptor antibody can reduces tumour volume and detect the presence of occult tumour metastases in vivo. Cancer Research 2002, 62:2390-2397.
23. Rabbani S.A., Xing R.H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. International Journal of Oncology 1998, 12:911-920.
24. Schmitt M., Sturmheit A.S., Welk A., Schnelldorfer C., Harbeck N. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods in Molecular Medicine 2006, 120:245-265.
25. Têtu B., Trudel D., Wang C.S. Protéases des cellules stromales réactionnelles du cancer: une cible thérapeutique attrayante. Bulletin du Cancer 2006, 93:944-948.
26. Ulisse S., Baldini E., Sorrenti S., D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Current Cancer Drug Targets 2009, 9:32-71.
27. Walker J.A., Jones J.L., Chappell S., Walsh T., Shawn J.A. Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Reviews 1997, 16:5-27.